Edema Clinical Trials Market Report 2026

The edema clinical trials market size has grown strongly in recent years. It will grow from $1.23 billion in 2025 to $1.34 billion in 2026 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to increasing prevalence of cardiovascular and renal disorders, expansion of clinical research infrastructure, rising pharmaceutical R&D investments, growth in investigator-led trials, improvements in clinical trial management systems.

The edema clinical trials market size is expected to see strong growth in the next few years. It will grow to $1.85 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to increasing demand for targeted edema therapies, rising use of decentralized clinical trial models, expansion of precision medicine approaches, growing integration of digital data capture tools, increased regulatory support for innovative trial designs. Major trends in the forecast period include increasing use of AI-assisted patient recruitment, rising adoption of adaptive trial designs, growing focus on biomarker-based endpoints, expansion of multi-center global trials, enhanced emphasis on real-world evidence integration.

The rising incidence of lifestyle-related diseases is expected to drive the growth of the edema clinical trials market in the coming years. Lifestyle-related diseases are conditions that develop from daily behaviors and choices, such as sedentary lifestyles, unhealthy diets, and substance use. Their prevalence is increasing due to poor dietary habits, including the widespread consumption of processed and high-calorie foods, which contribute to obesity, diabetes, and cardiovascular problems. Edema clinical trials support the management of these conditions by developing and evaluating treatments that address fluid buildup associated with obesity, diabetes, and cardiovascular disorders. For example, in March 2024, the UK-based Office for Health Improvement & Disparities reported that between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, while for type 2 diabetes it increased by 21%, and the percentage achieving target HbA1c levels rose to 37.9%, the highest value ever reported by the National Diabetes Audit (NDA). Therefore, the growing incidence of lifestyle-related diseases is fueling the edema clinical trials market.

Key players in the edema clinical trials market are focusing on innovative solutions such as refillable ocular implants to improve treatment efficacy and patient compliance in chronic edema-related eye conditions. A refillable ocular implant is a device implanted in the eye that delivers medication continuously over an extended period and allows periodic refilling without removal or replacement, providing sustained treatment for conditions like macular edema. For instance, in February 2025, Roche Holding AG, a Switzerland-based pharmaceutical company, received FDA approval for Susvimo, the first continuous-delivery treatment for diabetic macular edema (DME) and diabetic retinopathy (DR), both major causes of diabetes-related blindness. Susvimo offers an alternative to frequent eye injections with significantly fewer annual treatments, improving patient compliance and reducing treatment burden, potentially enhancing long-term outcomes for individuals with these chronic eye conditions.

In September 2025, Alcon Inc., a Switzerland-based eye care device company, acquired LumiThera Inc. for an undisclosed amount. Through this acquisition, Alcon aims to expand access to LumiThera’s Valeda photobiomodulation device for early and intermediate dry age-related macular degeneration (AMD), broadening its retinal treatment portfolio with clinic-based, noninvasive therapies to benefit millions of patients. LumiThera Inc. is a US-based ophthalmic medical device company involved in edema clinical trials.

Major companies operating in the edema clinical trials market are Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, CSL Limited, Regeneron Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Genentech Inc., Ionis Pharmaceuticals Inc., ANI Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Tactile Medical, REGENXBIO Inc., Koya Medical Inc., KalVista Pharmaceuticals Inc., Kodiak Sciences Inc., Pharvaris B.V., Oxurion NV, Outlook Therapeutics Inc., Adverum Biotechnologies Inc., Oculis Holding AG.

North America was the largest region in the edema clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the edema clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the edema clinical trials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the edema clinical trials market by increasing costs of imported laboratory equipment, diagnostic devices, trial monitoring systems, and investigational drug materials. Pharmaceutical companies and contract research organizations in North America and Europe are most affected due to dependence on specialized imported trial infrastructure, while Asia-Pacific faces higher operational costs for multinational study execution. These tariffs are contributing to increased trial budgets and extended timelines. At the same time, they are encouraging localized trial supply manufacturing, regional research collaborations, and greater investment in domestic clinical research capabilities.

The edema clinical trials market research report is one of a series of new reports that provides edema clinical trials market statistics, including edema clinical trials industry global market size, regional shares, competitors with a edema clinical trials market share, detailed edema clinical trials market segments, market trends and opportunities, and any further data you may need to thrive in the edema clinical trials industry. This edema clinical trials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Edema clinical trials are studies conducted to assess the safety, efficacy, and potential treatments for edema, which is the abnormal accumulation of fluid in the body’s tissues. These trials may evaluate drugs, medical devices, or therapeutic interventions aimed at reducing swelling, restoring fluid balance, or addressing underlying conditions such as heart, kidney, or liver disorders.

The primary phases of edema clinical trials are Phase I, Phase II, Phase III, and Phase IV. Phase I trials represent the initial stage, focusing on evaluating the safety, tolerability, and optimal dosage of a new therapy in a small group of participants. These trials cover various types of edema, including peripheral edema, pulmonary edema, cerebral edema, and nephrotic syndrome edema, and use study designs such as interventional, observational, and expanded access. Participants include pediatric, adult, and geriatric populations, while the main end-users are pharmaceutical companies, research institutions, contract research organizations (CROs), and academic research centers.

The edema clinical trials market includes revenues earned by entities by providing services such as patient recruitment and screening, safety and adverse event reporting, and regulatory compliance support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.